Research
Molecular
The post-ACCORD era represents a significant shift in the landscape of cardiovascular outcomes trials (CVOTs) in type 2 diabetes mellitus (T2DM), emphasizing the safety of glucose-lowering agents.
Practitioners should prioritize the safety profiles of glucose-lowering agents in T2DM management.
StrongSupportsmedium confidence
The post-ACCORD era is representative of a significant shift in the landscape of CVOTs in T2DM, with an emphasis on safety of glucose-lowering agents.
Why this rating
The review of multiple CVOTs indicates a high level of evidence.
Source
Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus
Karan Kapoor et al. · Cardiology · 2016
DOI 10.1159/000446471
reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Heterogeneous results were observed regarding the degree of glycemic control associated with optimal macrovascular disease risk reduction.Strong
- Recently completed and ongoing trials of dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter 2 inhibitors will inform clinical practice on safe and effective ways to reduce cardiovascular risk in T2DM.Strong
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →